A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 28, 2022

Primary Completion Date

February 5, 2025

Study Completion Date

August 31, 2027

Conditions
Polycystic Liver Disease
Interventions
DRUG

CAM2029

SC injection using a pre-filled pen

DRUG

Placebo

SC injection using a pre-filled pen

Trial Locations (11)

10029

Mount Sinai Hospital, New York

10065

The New York Presbyterian Hospital, New York

19104

Hospital of the University of Pennsylvania, Philadelphia

23602

Bon Secours Richmond Community Hospital, Richmond

30625

Hannover Medical School, Hanover

48149

Universitaetsklinikum Müenster, Münster

55905

Mayo Clinic, Rochester

75380

University of Texas Southwestern Medical Center, Dallas

B-3000

University Hospitals KU Leuven, Leuven

04103

Universitätsklinikum Leipzig, Leipzig

6525 GA

Radboud UMC, Department of Gastroenterology and Hepatology, Nijmegen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Camurus AB

INDUSTRY

NCT05281328 - A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD | Biotech Hunter | Biotech Hunter